Coverage / CRIS / Trade Card

CRIS

Curis Inc

OPPORTUNISTIC BUY Analysis generated 2026-10-04 Market data as of 2026-11-13 Market data 2 days old USD 0.45 Healthcare - Biotechnology
ACTIONABLEMethodology gates passed
53

Position levels

Currenttoday
USD 0.45
Buy <=wait / entry
-
Trim >=take some off
-
Thesis breaknot set
-

Scenario-weighted conviction

ProbabilityScoreContribution
Bull case19%100 / 10019.0
Base case49%62 / 10030.4
Bear case32%10 / 1003.2
Weighted conviction53 / 100 - OPPORTUNISTIC BUY

Top risks

  • Analyst HC Wainwright reiterates Buy rating and maintains $43 price target
  • Opened 11 active clinical sites in TakeAim CLL study and reaffirmed patient dosing guidance
  • Priced public offering of 3,733,334 shares plus warrants at $1.50 combined price
Read full report →

Research is for informational purposes only. Not financial advice. All analysis reflects the date of publication.

\n